Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)

Michael Volkov describes Novartis as “lucky” for a relatively positive outcome despite its 2016 SEC enforcement action in China and its culture of non-compliance, which could have led to assignment of an independent corporate compliance monitor and a higher penalty.